Medtronic secures 510(k) FDA clearance for MiniMed Go MDI and forms BCI partnership with Precision
Medtronic and Precision Neuroscience will co-develop an intraoperative brain-computer interface by integrating Precision’s Layer 7™ cortical interface with Medtronic’s StealthStation™ navigation system for real-time functional and structural mapping. The FDA also granted 510(k) clearance to Medtronic’s MiniMed Go™ Smart MDI system combining its InPen™ pen with Abbott’s Instinct CGM.
1. Medtronic Positioned for Multiple Acquisitions
At the JP Morgan Healthcare Conference in San Francisco, Medtronic executives emphasized the company’s “significant firepower” to pursue strategic acquisitions across its medical device portfolio. Medtronic reported holding approximately $13.5 billion in cash and short-term investments at the end of its last fiscal quarter, alongside an undrawn $10 billion credit facility. Leadership highlighted target areas including robotic surgery, digital health platforms and next-generation implantable devices. Management indicated that recent divestitures in noncore product lines have improved the balance sheet, enabling potential bolt-on deals in the $200 million to $2 billion range without diluting earnings per share.
2. Precision Neuroscience and Medtronic Launch Integrated Neurosurgical Solution
Medtronic entered a strategic partnership with Precision Neuroscience to co-develop a fully integrated neurosurgical platform. The collaboration combines Precision’s Layer 7™ cortical interface—capable of recording high-fidelity signals from up to 64 electrode channels—with Medtronic’s StealthStation™ real-time 3D surgical navigation system. This end-to-end solution aims to reduce intraoperative decision latency by 30% and improve target localization accuracy to within 0.5 millimeters. The system will undergo a multi-center clinical study in Q3 2026 across five leading academic medical centers, targeting commercial launch in early 2028.
3. FDA Clears MiniMed Go™ Smart MDI System to Enhance Diabetes Care
The U.S. Food and Drug Administration granted 510(k) clearance for Medtronic’s MiniMed Go™ Smart MDI system, which integrates the InPen™ smart insulin pen with Abbott’s Instinct continuous glucose sensor into a single mobile app. The system is cleared for use in individuals aged 7 years and older, with caregiver-supervised use down to age 2. In real-world analyses of over 1,800 users of the predecessor platform, Time in Range climbed from 55.7% to 67.2% when patients responded to more than 75% of missed-dose alerts within one hour, and to 71.5% when they addressed high-glucose alerts promptly. Commercial rollout is slated for spring 2026 across major U.S. diabetes clinics and digital health channels.